Key presentations of 3rd Annual Advances in Immuno-Oncology Congress

With registration closing soon, do not miss your opportunity to sign up for the 3rd Annual Advances in Immuno-Oncology Congress, 24 - 25 May 2018, London, and benefit from over 50 presentations highlighting the latest strategies and technologies impacting the immuno-oncology marketplace.

 

From in-depth considerations of checkpoint inhibitor and vaccine strategies to an increased focus on genomic approaches, our comprehensive programme ensures you will gain insights into the most debated topic areas within the field.

 

Key presentations include:

 

Checkpoint Inhibitors as a Therapeutic Strategy in Oncology | Kandeep Ganeshalingham, Executive Director, MSD

 

ATLAS - Challenging Current Dogma Through Cell-Based Neoantigen Identification and Characterisation | Wendy Broom, Director - Discovery, Genocea Biosciences

 

Gene Editing for Cancer Immunotherapy | Laurent Poirot, Head of Early Discovery, Cellectis

 

Development of Defined Microbial Drug Productsfor Cancer Immunotherapy | Bruce Roberts, Chief Scientific Officer, Vedanta Biosciences

 

View the agenda here: https://bit.ly/2oJlVB7

 

KEY REASONS TO ATTEND?

 

With over 200 attendees registered already, this is a must-attend opportunity to discover collaborative solutions for translational immuno-oncology and discuss the latest therapeutic innovations with senior level experts from companies including GlaxoSmithKline, MSD, Roche and Adaptimmune.

 

For further information on how to save on your attendance and what discounts we have available please contact a.saez@oxfordglobal.co.uk